Biotech Analysis Central Preview Series: TG Therapeutics

This is a preview blog series on what you can expect when subscribing to my "Biotech Analysis Central" service marketplace. For the full article you must subscribe to my service. This is just an intro of two snippets on the research articles that are written. Thus far, there are about 70+ research reports on both both small-cap and mid-cap biotech stocks with full analysis of the pipeline, catalysts, financials, and clinical trial analysis. If you want to read more then please subscribe to my marketplace service. As always I offer a 2-week free trial just to show you how helpful my service is. You can cancel anytime before the 2-week free trial is up and never be charged a dime.

First Section Of Marketplace Article (This article piece was originally written on September 9, 2019)

For this Biotech Analysis Central Update Series I wanted to go over a biotech by the name of TG Therapeutics (TGTX). The reason why I wanted to go over this name again is because of the many catalysts that are rapidly approaching. For starters, the biotech is set to report updated long-term follow up data for its phase 2 multiple sclerosis study at an upcoming medical conference on September 11-13, 2019. There is a separate phase 3 study that will have results to be reported in the middle/2nd half of 2020. The second reason is because of the potential for accelerated approval based on data from the UNITY-NHL study in patients with marginal zone lymphoma (MZL). This is important, because after speaking with the FDA, it was noted that a rolling submission for the drug umbralisib could be initiated by the end of this year. All of these events, plus many other programs in place, makes TG Therapeutics worth a look again.

Conclusion Of Marketplace Article 

The final verdict is that TG Therapeutics is a good biotech to get into. The reason why I have more confidence in this biotech is because of its potential to gain accelerated approval for umbralisib to treat patients with MZL. Like I stated it will be only for a small 8% portion of the entire NHL market, but regardless it is a very large market. As I signified above, the global NHL market is estimated to be worth $9.2 billion by 2020. Even targeting a small portion, MZL patients, will still offer the opportunity to generate millions of dollars in revenue. Putting this aside, the two studies set to report data in the next 6 to 12 months are large market opportunities. One is ublituximab being used to treat patients relapsing multiple sclerosis. Because 85% of patients are first diagnosed with RMS, the indication TG Therapeutics is going after, this will be a massive opportunity. Especially, when you consider that the global MS market is expected to reach $39.2 billion by 2026. Lastly, even the CLL market is worth multi-billion dollars. This does have a better shot compared to the other programs I have mentioned. Why do I make that claim? That's because besides using U2 (combination of umbralisib and ublituximab), there is another shot on goal with a triple combo. The triple combination is incorporating U2 along with an already FDA approved cancer drug you may have already heard of known as Imbruvica. If you know anything about Imbruvica, it was a drug developed by Pharmacyclics many years ago and ultimately the company was bought by AbbVie. There is no guarantee that the triple combination will end up being better, but I believe such a combo has a good shot at possibly improving clinical outcomes for blood cancer patients. The two shots on goal for CLL reduces investor risk and also offers potential to become superior over other cancer drugs. The last thing I will mention is the low market cap of TG Therapeutics, which is $598 million. I believe that should the upcoming clinical data prove to be successful, then this biotech should definitely be trading over a $1 billion market cap.